Clinical Trial: ECOG-ACRIN EA8185

ECOG-ACRIN EA8185

Status: Closed

NCT#04216290

Phase II Study of Bladder-SparIng ChemoradiatioN with Durvalumab in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)

EA8185 is closed to accrual, effective October 2, 2023.

The Montana Cancer Consortium (MCC) is an independent nonprofit organization whose mission is to bring state-of-the-art cancer care to Montana, Idaho and Wyoming through National Cancer Institute (NCI) sponsored clinical research.

Navigation

About Us

Contact Us

Copyright © Montana Cancer Consortium | All rights reserved